236 related articles for article (PubMed ID: 22316374)
1. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228.
Choudhary S; Sood S; Wang HC
Biochem Biophys Res Commun; 2013 Jun; 436(2):325-30. PubMed ID: 23743194
[TBL] [Abstract][Full Text] [Related]
3. LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway.
Li F; Yang W; Guo D; Hu Z; Xu H; Ye Z
Oncol Rep; 2011 Jun; 25(6):1629-37. PubMed ID: 21431282
[TBL] [Abstract][Full Text] [Related]
4. Bladder cancer: Cisplatin response is modulated by AR activity.
Fenner A
Nat Rev Urol; 2016 Aug; 13(8):437. PubMed ID: 27349366
[No Abstract] [Full Text] [Related]
5. Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin.
Shiota M; Tsunoda T; Song Y; Yokomizo A; Tada Y; Oda Y; Naito S
BJU Int; 2011 Apr; 107(7):1148-53. PubMed ID: 20726978
[TBL] [Abstract][Full Text] [Related]
6. Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer.
Tada Y; Yokomizo A; Shiota M; Tsunoda T; Plass C; Naito S
Int J Oncol; 2011 Sep; 39(3):727-33. PubMed ID: 21617853
[TBL] [Abstract][Full Text] [Related]
7. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
10. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors.
Saga Y; Hashimoto H; Yachiku S; Iwata T; Tokumitsu M
Int J Urol; 2004 Jun; 11(6):407-15. PubMed ID: 15157211
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling.
Fan Y; Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y
FEBS J; 2014 Apr; 281(7):1750-8. PubMed ID: 24495014
[TBL] [Abstract][Full Text] [Related]
12. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities.
Byun SS; Kim SW; Choi H; Lee C; Lee E
BJU Int; 2005 May; 95(7):1086-90. PubMed ID: 15839938
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
17. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Siddik ZH
Oncogene; 2003 Oct; 22(47):7265-79. PubMed ID: 14576837
[TBL] [Abstract][Full Text] [Related]
19. Nonplatinum therapy in advanced bladder cancer.
Srinivas S; Colocci N
Expert Rev Anticancer Ther; 2006 Jun; 6(6):887-94. PubMed ID: 16761932
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein gene expression in bladder cancer exposed to cisplatin.
Wood DP; Klein E; Fair WR; Chaganti RS
Mod Pathol; 1993 Jan; 6(1):33-5. PubMed ID: 8426855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]